

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

ustekinumab-kfce subcutaneous (Yesintek SC)

Notes:

- Quantity Limits: Yes
- ^Adequate trial is defined as the following:
 - Phototherapy – 8 weeks
 - Systemic non-biologics for psoriasis – 6 weeks
 - Methotrexate for psoriatic arthritis – 3 months
 - Biologics – 12 weeks
- *Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- **Methotrexate not required if patient has dactylitis (inflammation of finger or toe) and/or enthesitis (inflammation of entheses)

Initiation (new start) criteria: Formulary **ustekinumab-kfce (Yesintek)** will be covered on the prescription drug benefit when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient has failed an adequate trial^ of phototherapy (unless documented by prescriber phototherapy not appropriate)
 - Patient has failed an adequate trial^, or patient has an allergy or intolerance* to at least 1 of the following (or contraindication to all):
 - Methotrexate
 - Acitretin
 - Cyclosporine
2. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient has failed an adequate trial^, has an intolerance*, or has a contraindication to methotrexate**
3. Prescriber is a gastroenterologist and patient has a diagnosis of Crohn's disease or ulcerative colitis
 - Patient has received, or is scheduled to receive, one dose of ustekinumab product IV

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

ustekinumab-kfce subcutaneous (Yesintek SC)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Formulary **ustekinumab-kfce (Yesintek)** will be covered on the prescription drug benefit when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient currently stable on ustekinumab-kfce
2. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient currently stable on ustekinumab-kfce
3. Prescriber is a gastroenterologist and patient has a diagnosis of Crohn's disease or ulcerative colitis
 - Patient currently stable on ustekinumab-kfce

kp.org

Revised: 03/13/25
Effective: 03/27/25

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest